Jinghua Pharmaceutical Group (002349) Fair Value & Analysis
Healthcare · CN · Market cap 5.3B CNY
Fair value as of: Jul 22, 2026
From 26 valuation models · updated 19 days ago
Share price +6.8% over the past month.
A solid business, but screening 16% overvalued on our models.
What matters now
- A high-quality business (quality 70/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- Our model range runs from ¥4.35 (bear) to ¥7.26 (bull), base ¥5.80. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 70/100 (solid quality) with medium evidence: read the verdict with care.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range ¥3.81 – ¥24.95 · fair‑value band ¥4.35 – ¥7.26 · the ¥6.87 price screens above the ¥5.80 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.
Analysis
Jinghua Pharmaceutical Group (002349) currently trades at ¥6.87, while our model-based Fair Value estimate is ¥5.80, implying the stock looks roughly 15.6% overvalued today. The Quality Score stands at 70/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Jinghua Pharmaceutical Group generated revenue of 1.5B CNY at a net margin of 15.1%. Revenue grew 4.5% year over year. It earns a return on equity of 8.7%. The balance sheet holds a net cash position of 1.0B CNY. Fundamentals as of Jul 22, 2026
Our scenario range runs from ¥4.35 (bear case) to ¥7.26 (bull case); at ¥6.87, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 18% below its 52-week high and 9% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -16%, 002349 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (¥7.14) versus Dividend Discount (¥1.18). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 70 · Market factors (momentum, volatility) 46
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Jinghua Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and sale of APIs and pharmaceutical intermediates in China. Its primary products include Phenobarbital, Primidone, Fluorouracil, Phenylbutazone, Flucytosine, Piroxicam, and Propylthiouracil APIs.
Full company description
Jinghua Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and sale of APIs and pharmaceutical intermediates in China. Its primary products include Phenobarbital, Primidone, Fluorouracil, Phenylbutazone, Flucytosine, Piroxicam, and Propylthiouracil APIs. The company was formerly known as Nantong Jinghua Pharmaceutical Co., Ltd. The company was founded in 1957 and is based in Nantong, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Jinghua Pharmaceutical Group reported revenue of ¥1.5B in FY2025 versus ¥1.4B in FY2021, a compound +1.8%/yr. Reported net income was ¥219M in FY2025, compounding +8.1%/yr from FY2021.
002349 screens 16% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →
Peer Group
Drug Manufacturers - Specialty & Generic · 626 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Jinghua Pharmaceutical Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Jinghua Pharmaceutical Group (002349) overvalued or undervalued?
What is the fair value of 002349?
What is the quality score of 002349?
What is the revenue of Jinghua Pharmaceutical Group (002349)?
What is the net profit margin of 002349?
Does Jinghua Pharmaceutical Group pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Jinghua Pharmaceutical Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.